Biotech Funding Cycles & Pharma M&A

Biopharma M&A and funding cycles are rebounding strongly in 2026, driven by massive Big Pharma capital reserves, urgent patent expiration cliffs, and a shift toward early-stage clinical assets, despite ongoing regulatory and macroeconomic headwinds.